Document:

<PAGE>   1
                                                                    Exhibit 10.4

Amendment One to Development Agreement                               Page 1 of 7

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                              AMENDMENT ONE
                                    TO

                          DEVELOPMENT AGREEMENT

    This Amendment One made as of the day last subscribed below ("Effective
Date") between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, a Delaware
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

      WHEREAS, SRI and LSI have entered in to a development agreement having an
effective date of October 6, 2000 (hereinafter "Development Agreement") and
which the parties hereby amend; and

      WHEREAS, the parties intend that this Amendment One provides an extension
of the Phase I Development Period of the Development Agreement as originally
executed

      NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1. For consistency and unless otherwise defined herein all initially capitalized
   terms shall have the meaning set forth in the Development Agreement.

2. The parties hereby agree that the Phase I Development Period shall mean the
   period commencing on October 6, 2000 and unless terminated earlier as
   provided the Development Agreement or extended by the mutual written
   agreement of the parties, shall expire on March 30, 2001.

3. The parties hereby agree that the research fee authorized by LSI for the
   Phase I Development Period as set forth in 2.2.1 of the Development
   Agreement, has not been changed.

4. The parties hereby agree that the Development Plan for Phase I shall be
   amended as follows and a copy of the amended Development Plan is attached
   hereto as Exhibit A: (i) Task 10 is deleted and may be included in Phase II
   depending on the experimental results of Task 9; (ii) Task 11 Output with
   respect to the record of a preliminary design review has been deleted from
   Phase I and shall be included in Phase II; (iii) Tasks 14-18 are to be
   deleted from Phase I and shall be included in Phase II; and. (iv) Tasks 20
   and 21 shall be added to the Development Plan for Phase I to cover the single
   solvent work and material compatibility.

5. Section 3.5 shall be amended to read:

        "3.5.  [ * ]."

6. Section 11.1, Notices, the LSI telephone number for Phil Radlick shall be
   amend to read "925-249-4010" and the facsimile number to read "925-249-4040".
<PAGE>   2
Amendment One to Development Agreement                               Page 2 of 7

*CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Unless expressly amended by this Amendment One, all other terms and conditions
of the Development Agreement shall remain in full force and effect.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                       LSI:
SRI International                          Lipid Sciences, Incorporated

By /s/ Valerie J. Hooper                   By: /s/ Phil Radlick
  -------------------------                   ----------------------------------
    Valerie J. Hooper                               Phil Radlick, Ph.D.
    Associate Director,                       President/ Chief Executive Officer
    Corporate Development

Date: March 8, 2001                         Date: March 8, 2001

<PAGE>   3
Amendment One to Development Agreement                               Page 3 of 7

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                EXHIBIT A

              AMENDED TASKS FOR DEVELOPMENT PLAN FOR PHASE 1

                                   [*]

<PAGE>   4
                                                                     Page 4 of 7

                     Amendment One to Development Agreement

* Certain Information in this Exhibit has been omitted and filed separately
with the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]
<PAGE>   5

                                                                     Page 5 of 7

                     Amendment One to Development Agreement

*Certain Information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]

<PAGE>   6
                                                                     Page 6 of 7

                     Amendment One to Development Agreement
*Certain information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]

<PAGE>   7
                                                                     Page 7 of 7

                     Amendment One to Development Agreement

*Certain information in this Exhibit has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                               Exhibit A (con't)

                                      [*]<PAGE>   1
                                                                    Exhibit 10.5

                                                                     Page 1 of 2
Amendment Two to Development Agreement

                                  AMENDMENT TWO
                                       TO
                              DEVELOPMENT AGREEMENT

      This Amendment Two made as of March 28, 2001 ("Effective Date") between
SRI International, a California, non-profit and public benefit corporation,
having a place of business located at 333 Ravenswood Avenue, Menlo Park, CA
94025 (hereinafter "SRI") and Lipid Sciences Incorporated, a Delaware
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 (hereinafter individually and collectively "Development Agreement") and
which the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Two provides for the
start of Phase II Development Period of the Development Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.   For consistency and unless otherwise defined herein all initially
     capitalized terms shall have the meaning set forth in the Development
     Agreement.

2.   The parties hereby agree that the Phase II Development Period shall mean
     the period commencing on March 28, 2001 and unless terminated earlier as
     provided in the Development Agreement or extended by the mutual written
     agreement of the parties, shall expire on the end dates provided in the
     Phase II Development Plan. It is further agreed that the parties shall have
     a forty-five day (45) interim period from the Effective Date until such
     time that timelines, deliverables tasks, milestones, and costs associated
     therewith shall be described and identified in a document identified as the
     Phase II Development Plan, and on written agreement of the parties shall be
     added as an amendment to the Development Agreement.

3.   Paragraph 2.2.2 shall be deleted in its entirety and replaced with the
     following:

          During the forty-five (45) day interim period following the Effective
          Date, SRI shall be authorized to expend up to five-hundred thousand
          dollars ($500,000) to continue development of design input and
          subsystem refinement on both the single and multi-solvent systems, as
          well as continuing feasibility studies in hollow fiber contactors.
<PAGE>   2
Amendment Two to Development Agreement                               Page 2 of 2

4.   Paragraph 2.2.4 of the Development Agreement, second sentence beginning on
     line 4 through the end of the paragraph shall be deleted in its entirety
     and replaced with the following sentence:

           "2.2.4 Within five (5) business days of the execution of this
         Amendment Two for the interim forty-five day Phase II effort, LSI shall
         pay to SRI three hundred and fifty thousand dollars ($350,000.00) as an
         advance deposit against the project charges to be incurred during the
         interim period. Upon receipt of such deposit, SRI shall initiate work
         and shall deliver to LSI a paid-memo invoice for receipt of the deposit
         paid. An invoice for the costs incurred for each month of the Agreement
         shall be submitted to LSI at the end of that month, payment shall be
         due within ten (10) days after receipt of invoice."

Unless expressly amended by this Amendment Two, all other terms and conditions
of the Development Agreement shall remain in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.

SRI:                                  LSI:
SRI International                     Lipid Sciences, Incorporated

By: /s/ Margaret Baxter-Pearson          By: /s/ Phil Radlick
    -----------------------------            -------------------------------
Name: Margaret Baxter-Pearson                         Phil Radlick, Ph.D.

Title: Contracts Manager                     President & Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]